Table 3A.
Transplant outcomes in the whole cohort
| Dose level 0 (N=2) | Dose level 2 (N=4) | Dose level 3 (N=4) | Dose level 4 (N=7) | Dose level 5 (N=58) | Dose level 6 (N=5) | |
|---|---|---|---|---|---|---|
| Graft Failure | 1 | 1 | 0 | 0 | 2 | 0 |
| Time to Neutrophil Engraftment,(days) | 13 | 17 | 16 | 12 | 13 | 13 |
| Time to platelet Engraftement, (days) | 8 | 18 | 20 | 22 | 15 | 18 |
| Grade 2–4 aGVHD | 0 | 2 | 3 | 2 | 17 | 2 |
| Grade 3–4 aGVHD | 0 | 1 | 0 | 0 | 5 | 2 |
| Time to aGVHD, days | - | 34.5 | 48 | 26 | 46 | 35.5 |
| Chronic GVHD | 0 | 0 | 0 | 2 | 19 | 1 |
| Time to cGVHD, mos | - | - | - | 4.3 | 7.1 | 4.3 |
| Progression, n | 1 | 3 | 2 | 5 | 26 | 4 |
| Median time to progression, days | 70 | 26 | 25.5 | 54 | 64.5 | 81 |
| Dead, n | 2 | 4 | 2 | 6 | 43 | 5 |
| Dead at 100days without relapse | 1 | 1 | 0 | 0 | 6 | 0 |
| Dead at 1year without relapse | 1 | 1 | 0 | 2 | 14 | 0 |
| Median time to death, days | 167 | 48 | 65 | 165 | 157 | 258 |